Evidence map›Paper›PMID 26572163›Full record

ArticleBMC genomics2015

Integrated genomics approach to identify biologically relevant alterations in fewer samples.

Pratik Chandrani, Pawan Upadhyay, Prajish Iyer, Mayur Tanna, Madhur Shetty, Gorantala Venkata Raghuram, Ninad Oak, Ankita Singh, Rohan Chaubal, Manoj Ramteke and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Drug-sensitive FGFR3 mutations in lung adenocarcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Pratik ChandraniAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. pratikchandrani@gmail.com.
Pawan UpadhyayAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. pawanupadhyay70@gmail.com.
Prajish IyerAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. prajish89@gmail.com.
Mayur TannaAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. tannamayur90@gmail.com.
Madhur ShettyAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. madhurshetty1986@gmail.com.
Gorantala Venkata RaghuramAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. raghuram.venkata@gmail.com.
Ninad OakAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. ninadoak@gmail.com.
Ankita SinghAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. ankita0007@gmail.com.
Rohan ChaubalAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. rohanchaubal@gmail.com.
Manoj RamtekeAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. mnj.rmtk@gmail.com.
Sudeep GuptaDepartment of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India. sudeepgupta04@yahoo.com.
Amit DuttAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, 410210, India. adutt@actrec.gov.in.
Advanced Centre for Treatment, Research and Education in Cancer · INTata Memorial Hospital · IN

Funding

DBT-Wellcome Trust India Alliance IA/I/11/2500278Wellcome TrustWellcome Trust IA/I/11/2500278
6 · The paper itself

Abstract

backgroundSeveral statistical tools have been developed to identify genes mutated at rates significantly higher than background, indicative of positive selection, involving large sample cohort studies. However, studies involving smaller sample sizes are inherently restrictive due to their limited statistical power to identify low frequency genetic variations.

resultsWe performed an integrated characterization of copy number, mutation and expression analyses of four head and neck cancer cell lines - NT8e, OT9, AW13516 and AW8507 - by applying a filtering strategy to prioritize for genes affected by two or more alterations within or across the cell lines. Besides identifying TP53, PTEN, HRAS and MET as major altered HNSCC hallmark genes, this analysis uncovered 34 novel candidate genes altered. Of these, we find a heterozygous truncating mutation in Nuclear receptor binding protein, NRBP1 pseudokinase gene, identical to as reported in other cancers, is oncogenic when ectopically expressed in NIH-3 T3 cells. Knockdown of NRBP1 in an oral carcinoma cell line bearing NRBP1 mutation inhibit transformation and survival of the cells.

conclusionsIn overall, we present the first comprehensive genomic characterization of four head and neck cancer cell lines established from Indian patients. We also demonstrate the ability of integrated analysis to uncover biologically important genetic variation in studies involving fewer or rare clinical specimens.

Indexed as

Carcinoma, Squamous CellCell Line, TumorCell SurvivalDNA, NeoplasmGene DosageGenomicsHead and Neck NeoplasmsHumansKaryotypeMutationOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotideReceptors, Cytoplasmic and NuclearSequence Analysis, DNASquamous Cell Carcinoma of Head and NeckTranscriptomeDNA, NeoplasmNRBP1 protein, humanReceptors, Cytoplasmic and NuclearVesicular Transport Proteins

Identifiers

PMID26572163
PMCPMC4647579
OpenAlexW2177681889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.